Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial

被引：2
|
作者：
Ying, Zhitao [1 ]
Zou, Dehui [2 ,3 ]
Yang, Haiyan [4 ]
Wu, Jianqiu [5 ]
Guo, Ye [6 ]
Li, Wenyu [7 ]
Liu, Hui [8 ]
Wang, Chris [9 ]
Ma, Laura [9 ]
Yang, Su [9 ]
Zhou, Zisong [9 ]
Qin, Yun [9 ]
Song, Yuqin [1 ]
Zhu, Jun [1 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, 52 Fucheng Rd, Beijing 100142, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Dept Lymphoma & Myeloma, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Chinese Acad Sci, Canc Hosp,Inst Basic Med & Canc IBMC,Dept Lymphom, Hangzhou, Zhejiang, Peoples R China
[5] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Jiangsu Red Cross Canc Ctr,Dept Med Oncol, Nanjing, Peoples R China
[6] Tongji Univ, Shanghai Dongfang Hosp, Dept Oncol, Shanghai, Peoples R China
[7] Guangdong Acad Sci, Guangdong Prov Peoples Hosp, Dept Lymphoma, Guangzhou, Guangdong, Peoples R China
[8] Beijing Hosp, Dept Hematol, Beijing, Peoples R China
[9] JW Therapeut Shanghai Co Ltd, Shanghai, Peoples R China
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2022年 / 97卷 / 12期
关键词：
D O I：
10.1002/ajh.26711
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E436 / E438
页数：3
相关论文
共 50 条
  • [1] Efficacy and Safety of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma in China
    Song, Yuqin
    Ying, Zhitao
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Wu, Jianqiu
    Tian, Alex
    Huang, Tony
    Zhou, Zisong
    Ma, Meilin
    Yang, Su
    Qin, Yun
    Zhu, Jun
    BLOOD, 2022, 140 : 10329 - 10331
  • [2] Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China
    Song, Yuqin
    Ying, Zhitao
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Wu, Jianqiu
    Yang, Su
    Zhang, Pian
    Ma, Meilin
    Zhou, Zisong
    Zheng, Hongxia
    Zhu, Jun
    BLOOD, 2021, 138
  • [3] Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China
    Ying, Zhitao
    Zhou, Keshu
    Li, Lanfang
    Li, Wenyu
    Yang, Su
    Liu, Yun
    Gu, Yongen
    Zhou, Zisong
    Tian, Alex
    Song, Yuqin
    Zhu, Jun
    BLOOD, 2022, 140 : 7470 - 7471
  • [4] Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China
    Song, Yuqin
    Zhou, Keshu
    Li, Lanfang
    Liang, Aibin
    Qin, Yun
    Xia, Zhen
    Gu, Yongen
    Zhou, Zisong
    Tian, Alex
    Zhu, Jun
    BLOOD, 2023, 142
  • [5] Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China
    Lin, Ziyi
    Zuo, Chenyu
    Jiang, Yifan
    Su, Wen
    Yao, Xing
    Man, Yu
    Wu, Qiong
    Xuan, Jianwei
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 41 - 48
  • [6] Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching-Adjusted Indirect Analysis
    Gao, Fenghua
    Sun, Cong
    Liu, Jing
    Yu, Jingwei
    He, Jin
    Meng, Xiangrui
    Liu, Xia
    Han, Xue
    Li, Lanfang
    Qiu, Lihua
    Qian, Zhengzi
    Zhou, Shiyong
    Xia, Zhen
    Yang, Su
    Zhou, Zisong
    Tian, Alex
    Qin, Yun
    Wang, Xianhuo
    Zhang, Huilai
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (02)
  • [7] Phase I Hypofractionation Trial of Relapsed/Refractory Lymphoma: Preliminary Results
    Rajeev-Kumar, G.
    McKeever, M. R.
    Koshy, M.
    McCall, A. R.
    Arif, F.
    Smith, S. M.
    Kline, J.
    Riedell, P.
    Hasans, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S67 - S68
  • [8] Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China
    Song, Yuqin
    Ying, Zhitao
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Zhou, Daobin
    Wang, Zhao
    Zhang, Mingzhi
    Wu, Jianqiu
    Liu, Hui
    Zhang, Pian
    Yang, Su
    Zhou, Zisong
    Zheng, Hongxia
    Zhu, Jun
    BLOOD, 2021, 138
  • [9] Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
    Kim, T. M.
    Taszner, M.
    Novelli, S.
    Cho, S. -G
    Villasboas, J. C.
    Merli, M.
    Jimenez-Ubieto, A.
    Tessoulin, B.
    Poon, L. M.
    Tucker, D.
    Walewski, J.
    Yi, S.
    Song, Y.
    Chong, G.
    Bachy, E.
    Guidez, S.
    Alonso, A.
    Jagadeesh, D.
    Zhang, W.
    Magnano, L.
    Iskierka-Jazdzewska, E.
    Tani, M.
    Shen, B.
    Uppala, A.
    Zhu, M.
    Shariff, S.
    Brouwer-Visser, J.
    Chaudhry, A.
    Mohamed, H.
    Ambati, S.
    Luminari, S.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 1039 - 1047
  • [10] Phase I/II Clinical Trial of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, and Follicular Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 17 - 18
12345